Monte Rosa Therapeutics (GLUE) Operating Leases (2022 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Operating Leases of $34.6 million for Q1 2026, down 8.99% year-over-year from $38.0 million in Q1 2025, and down 0.61% quarter-over-quarter from $34.8 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Operating Leases (2022 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2026.
- In Q1 2026, Operating Leases fell 8.99% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 8.99% YoY), while the FY2025 annual figure was $34.8 million, down 10.79% from the prior year.
- Operating Leases for Q1 2026 stood at $34.6 million, down from $34.8 million in the prior quarter.
- The five-year high for Operating Leases was $46.1 million in Q2 2022, with the low at $5.5 million in Q1 2022.
- The 5-year median for Operating Leases is $40.9 million (2024), against an average of $38.5 million.
- The sharpest annual moves came in 2023 and 2025: Operating Leases jumped 693.02% in 2023, then dropped 10.79% in 2025.
- Monte Rosa Therapeutics' Operating Leases stood at $43.9 million in 2022, then decreased by 2.27% to $42.9 million in 2023, then dropped by 9.04% to $39.0 million in 2024, then decreased by 10.79% to $34.8 million in 2025, then retreated by 0.61% to $34.6 million in 2026.
- Business Quant data shows GLUE's Operating Leases at $34.6 million in Q1 2026, $34.8 million in Q4 2025, and $35.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.36 Mn |
| Mar 31, 2026 | 34.58 Mn |
| Dec 31, 2025 | 34.79 Mn |
| Sep 30, 2025 | 35.93 Mn |
| Jun 30, 2025 | 37.04 Mn |
| Mar 31, 2025 | 38.00 Mn |
| Dec 31, 2024 | 39.00 Mn |
| Sep 30, 2024 | 40.05 Mn |
| Jun 30, 2024 | 40.89 Mn |
| Mar 31, 2024 | 41.84 Mn |
| Dec 31, 2023 | 42.88 Mn |
| Sep 30, 2023 | 43.52 Mn |
| Jun 30, 2023 | 44.37 Mn |
| Mar 31, 2023 | 43.28 Mn |
| Dec 31, 2022 | 43.87 Mn |
| Sep 30, 2022 | 42.59 Mn |
| Jun 30, 2022 | 46.10 Mn |
| Mar 31, 2022 | 5.46 Mn |